- Home
- ANAB vs INDI Comparison
ANAB vs INDI Comparison
Compare ANAB & INDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- INDI
- Stock Information
- Founded
- ANAB 2005
- INDI 2007
- Country
- ANAB United States
- INDI United States
- Employees
- ANAB N/A
- INDI N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- INDI Semiconductors
- Sector
- ANAB Health Care
- INDI Technology
- Exchange
- ANAB Nasdaq
- INDI Nasdaq
- Market Cap
- ANAB 621.1M
- INDI 610.0M
- IPO Year
- ANAB 2017
- INDI N/A
- Fundamental
- Price
- ANAB $23.41
- INDI $3.74
- Analyst Decision
- ANAB Buy
- INDI Strong Buy
- Analyst Count
- ANAB 10
- INDI 6
- Target Price
- ANAB $44.25
- INDI $6.08
- AVG Volume (30 Days)
- ANAB 566.9K
- INDI 4.6M
- Earning Date
- ANAB 08-04-2025
- INDI 08-07-2025
- Dividend Yield
- ANAB N/A
- INDI N/A
- EPS Growth
- ANAB N/A
- INDI N/A
- EPS
- ANAB N/A
- INDI N/A
- Revenue
- ANAB $111,872,000.00
- INDI $218,406,000.00
- Revenue This Year
- ANAB N/A
- INDI $7.46
- Revenue Next Year
- ANAB $24.39
- INDI $32.80
- P/E Ratio
- ANAB N/A
- INDI N/A
- Revenue Growth
- ANAB 387.20
- INDI N/A
- 52 Week Low
- ANAB $12.21
- INDI $1.53
- 52 Week High
- ANAB $41.31
- INDI $7.45
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- INDI 64.73
- Support Level
- ANAB $21.87
- INDI $3.43
- Resistance Level
- ANAB $24.69
- INDI $3.78
- Average True Range (ATR)
- ANAB 1.19
- INDI 0.31
- MACD
- ANAB -0.09
- INDI 0.01
- Stochastic Oscillator
- ANAB 61.20
- INDI 65.25
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About INDI indie Semiconductor Inc.
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.